Preventing the Recurrence
of Melanoma

About Polynoma

An immuno-oncology company developing a novel vaccine for the adjuvant treatment of melanoma.

Learn More

The Technology

Polyvalent shed antigens stimulate both humoral and cellular immune responses.

Clinical Trials

MAVIS (Melanoma Antigen Vaccine Immunotherapy Study) is a multicenter, double-blind, placebo-controlled adaptive Phase III trial to assess the safety and efficacy of seviprotimut-L.

Read More

Publications

Journal for ImmunoTherapy of Cancer (October 1st 2021): Multicenter, double- blind, placebo- controlled trial of seviprotimut- L polyvalent melanoma vaccine in patients with post- resection melanoma at high risk of recurrence

View All

News

Polynoma Receives SPA Agreement from the U.S. FDA for a Pivotal Phase 3 Clinical Study of Seviprotimut-L

View All